CCTA

New Data from Clinical Studies Further Validate HeartFlow’s All-in-One Portfolio of Precision Coronary Care Solutions

Retrieved on: 
Friday, July 28, 2023
CT, Plaque, Society, Multifocal stenosing ulceration of the small intestine, Anatomy, Society of Cardiovascular Computed Tomography, CAD, Circulant matrix, CCTA, Physiology, Roadmap, IVUS, FFR, Calcium, SCCT, Patient, Risk, Atherosclerosis, Conference, Medical imaging, Pharmaceutical industry

MOUNTAIN VIEW, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- Respective results from the REVEALPLAQUE, DECODE, and SMART-CT clinical studies demonstrate the accuracy, utility, and efficiency of HeartFlow’s portfolio of coronary computed tomography angiography (CCTA)-based precision coronary care technologies.

Key Points: 
  • MOUNTAIN VIEW, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- Respective results from the REVEALPLAQUE, DECODE, and SMART-CT clinical studies demonstrate the accuracy, utility, and efficiency of HeartFlow’s portfolio of coronary computed tomography angiography (CCTA)-based precision coronary care technologies.
  • HeartFlow is the first company to offer a suite of technologies to help clinicians non-invasively identify stenoses in the coronary arteries ( RoadMap™Analysis ), assess coronary blood flow ( FFR C T Analysis ), and characterize and quantify coronary atherosclerosis ( Plaque Analysis ).
  • Together, this comprehensive solution offers valuable data not currently available with traditional non-invasive diagnostics tools, allowing clinicians to see the full picture of their patients’ coronary artery disease (CAD).
  • "Until now, clinicians have not had access to a complete view of a patient’s heart health with accurate data on coronary anatomy, physiology, and plaque.

HeartFlow, Inc. to Announce New Data on Diagnosing and Managing Coronary Artery Disease at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting

Retrieved on: 
Monday, July 24, 2023
Charleston Area Medical Center, CT scan, Cardiac imaging, University, Culture, MACC, FACC, Booth, CCTA, Research, Ability, SCCT, Plaque, Physician, Cardiology, University of British Columbia, AM, Coronary artery disease, Medical imaging, Doctor of Philosophy, Patient, MPH

MOUNTAIN VIEW, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the only non-invasive precision coronary care solution to provide both anatomic and physiologic insights, today announced that new data on HeartFlow Plaque Analysis and its RoadMapTM Analysis will be presented at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Boston, MA.

Key Points: 
  • MOUNTAIN VIEW, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the only non-invasive precision coronary care solution to provide both anatomic and physiologic insights, today announced that new data on HeartFlow Plaque Analysis and its RoadMapTM Analysis will be presented at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Boston, MA.
  • “The data being presented at SCCT are the latest findings in a robust body of evidence that show HeartFlow technologies help clinicians further improve diagnostic accuracy and clinical decision-making to ensure the right patients are getting the right care at the right time,” said Campbell Rogers, Chief Medical Officer of HeartFlow.
  • Featured speakers include Jonathon Leipsic, M.D., FSCCT, former president of SCCT; Jagat Narula, M.D., PhD, MACC, Executive Vice President and Chief Academic Officer at UTHealth Houston; Wesley O’Neal, M.D., MPH, FACC, Director, Cardiac CT and Nuclear Cardiology at Cone Health Heart & Vascular Center and Sarah Rinehart, M.D., FACC, FSCCT, Director of Cardiac Imaging, Director of Cardiology Fellowship at Charleston Area Medical Center.
  • Company representatives will also be available during the conference at Booth 207.

Caristo Diagnostics Piloting New Cardiac Disease Diagnostic Technology in UK NHS Hospitals

Retrieved on: 
Wednesday, July 12, 2023
Inflammation, CT, Plaque, NHS England, National Health Service, Cardiovascular disease, University Hospitals Cleveland Medical Center, CAD, Liverpool Heart and Chest Hospital NHS Foundation Trust, FAI, CCTA, Atherosclerosis, Milton Keynes University Hospital, Hospital, Patient, Oxford University Hospitals NHS Foundation Trust, Risk, Royal Wolverhampton NHS Trust, University Hospitals of Leicester NHS Trust, Algorithm, Artificial intelligence, NHS, Coronary artery disease, NICE, Pharmaceutical industry, Medical imaging, EU

OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.

Key Points: 
  • OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.
  • The new pilot supported by NHS England will involve five NHS trusts, including University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust.
  • The latest CaRi-Heart platform was released recently for UK and EU markets and can detect both coronary inflammation and atherosclerosis (plaque), based on routine cardiac CT scans.
  • "Caristo and our clinical partners are excited about this ground-breaking clinical initiative supported by NHS England", said Frank Cheng, Caristo Diagnostics CEO, "We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world".

Caristo Diagnostics Piloting New Cardiac Disease Diagnostic Technology in UK NHS Hospitals

Retrieved on: 
Wednesday, July 12, 2023
Inflammation, CT, Plaque, NHS England, National Health Service, Cardiovascular disease, University Hospitals Cleveland Medical Center, CAD, Liverpool Heart and Chest Hospital NHS Foundation Trust, FAI, CCTA, Atherosclerosis, Milton Keynes University Hospital, Hospital, Patient, Oxford University Hospitals NHS Foundation Trust, Risk, Royal Wolverhampton NHS Trust, University Hospitals of Leicester NHS Trust, Algorithm, Artificial intelligence, NHS, Coronary artery disease, NICE, Pharmaceutical industry, Medical imaging, EU

OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.

Key Points: 
  • OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.
  • The new pilot supported by NHS England will involve five NHS trusts, including University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust.
  • The latest CaRi-Heart platform was released recently for UK and EU markets and can detect both coronary inflammation and atherosclerosis (plaque), based on routine cardiac CT scans.
  • "Caristo and our clinical partners are excited about this ground-breaking clinical initiative supported by NHS England", said Frank Cheng, Caristo Diagnostics CEO, "We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world".

Caristo Diagnostics Applauds FDA Approval of Colchicine as First Anti-Inflammatory Drug for Cardiovascular Disease

Retrieved on: 
Thursday, June 22, 2023
Inflammation, Plaque, University, Myocardial infarction, MI, Stroke, Cardiovascular disease, British Heart Foundation, C-reactive protein, FAI, CCTA, Biomarker, Meta-analysis, Colchicine, Atherosclerosis, HRP, CRP, Patient, Risk, Algorithm, Tumor necrosis factor, Fat, Juan Carlos Ferrero, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Medical imaging

OXFORD, England, June 22, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, applauds the FDA's decision to approve colchicine as first anti-inflammatory drug for cardiovascular disease. Caristo reaffirms its commitment to lead innovations in CCTA based coronary inflammation detection and cardiovascular risk prediction, so every coronary inflammation patient can be identified and treated by appropriate therapy including the anti-inflammatory drug approved by the FDA.

Key Points: 
  • OXFORD, England, June 22, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, applauds the FDA's decision to approve colchicine as first anti-inflammatory drug for cardiovascular disease.
  • Caristo reaffirms its commitment to lead innovations in CCTA based coronary inflammation detection and cardiovascular risk prediction, so every coronary inflammation patient can be identified and treated by appropriate therapy including the anti-inflammatory drug approved by the FDA.
  • "The FDA approval of colchicine is an important tool for us to reduce coronary inflammation, a main culprit for heart attack."
  • Caristo Diagnostics was founded in 2018 to commercialize the proprietary CaRi-Heart® coronary inflammation diagnostic technology based on PVAT quantification.

Caristo Diagnostics Applauds FDA Approval of Colchicine as First Anti-Inflammatory Drug for Cardiovascular Disease

Retrieved on: 
Thursday, June 22, 2023
Inflammation, Plaque, University, Myocardial infarction, MI, Stroke, Cardiovascular disease, British Heart Foundation, C-reactive protein, FAI, CCTA, Biomarker, Meta-analysis, Colchicine, Atherosclerosis, HRP, CRP, Patient, Risk, Algorithm, Tumor necrosis factor, Fat, Juan Carlos Ferrero, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Medical imaging

OXFORD, England, June 22, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, applauds the FDA's decision to approve colchicine as first anti-inflammatory drug for cardiovascular disease. Caristo reaffirms its commitment to lead innovations in CCTA based coronary inflammation detection and cardiovascular risk prediction, so every coronary inflammation patient can be identified and treated by appropriate therapy including the anti-inflammatory drug approved by the FDA.

Key Points: 
  • OXFORD, England, June 22, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, applauds the FDA's decision to approve colchicine as first anti-inflammatory drug for cardiovascular disease.
  • Caristo reaffirms its commitment to lead innovations in CCTA based coronary inflammation detection and cardiovascular risk prediction, so every coronary inflammation patient can be identified and treated by appropriate therapy including the anti-inflammatory drug approved by the FDA.
  • "The FDA approval of colchicine is an important tool for us to reduce coronary inflammation, a main culprit for heart attack."
  • Caristo Diagnostics was founded in 2018 to commercialize the proprietary CaRi-Heart® coronary inflammation diagnostic technology based on PVAT quantification.

Cardio Diagnostics Holdings, Inc Democratizes CHD Detection with Nationwide Launch of PrecisionCHD™

Retrieved on: 
Wednesday, June 21, 2023
Biotechnology, Health, Cardiology, Medical Devices, CT, Radiation, Doctor of Philosophy, GoodRx, Moyamoya disease, COVID-19, Cardiovascular disease, Health equity, Splenic infarction, CCTA, Chest pain, Innovation, Biomarker, COVID-19 testing, CDC, Radiology, Death, Parity, Cardio, Social justice, Angiography, Patient, Korea Disease Control and Prevention Agency, AI, ACI, CHD, Conditional sentence, Medical device, Medical imaging, Pharmaceutical industry

Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer in AI-driven precision cardiovascular medicine tests, today announces the nationwide launch of PrecisionCHD™.

Key Points: 
  • Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer in AI-driven precision cardiovascular medicine tests, today announces the nationwide launch of PrecisionCHD™.
  • It is the second product to be released from Cardio Diagnostics’ cutting-edge suite of AI-driven molecular cardiovascular disease technologies.
  • Despite its human and economic burden, the reach of current CHD detection tests, predominantly imaging-based approaches such as Coronary Computed Tomographic Angiography (CCTA), is limited.
  • It empowers primary care clinicians to assess CHD status, democratizing cutting-edge heart disease detection technologies at increased cardiovascular disease rates.

Cleerly Wins 2023 Artificial Intelligence Breakthrough Award

Retrieved on: 
Wednesday, June 21, 2023
Health, FDA, Technology, Health Technology, Artificial Intelligence, Cardiology, Biotechnology, Heart, Natural language processing, Artificial Intelligence for IT Operations, Synthetic media, FACC, CAD, Splenic infarction, CCTA, Medicine, Computer vision, Patient, Physician, Machine learning, Algorithm, Risk, Robotics, Generative, Artificial intelligence, Deep learning, AI, FESC, Medical device, Medical imaging, MD

Cleerly , the company creating a new standard of care for heart disease, today announced that it has been named “Best Overall AI Solution” in the sixth annual AI Breakthrough Awards program conducted by AI Breakthrough , a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market today.

Key Points: 
  • Cleerly , the company creating a new standard of care for heart disease, today announced that it has been named “Best Overall AI Solution” in the sixth annual AI Breakthrough Awards program conducted by AI Breakthrough , a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market today.
  • Cleerly’s digital care platform helps physicians precisely identify, define, and treat heart disease at its earliest stages, when it is most treatable.
  • The platform leverages non-invasive coronary computed tomography angiography (CCTA) to perform comprehensive coronary artery phenotyping through AI-powered and FDA-cleared solutions.
  • “By leveraging AI for advanced imaging, Cleerly is pioneering the transformation of heart disease by using this approach towards precision prevention and paving the way for a new future of cardiovascular care.”

The 2023 Radiology Practice Development Report: Radiologists Read an Average of 4.7 Subspecialties in Daily Practice; Less than Half of Radiologists Feel "Very Confident"

Retrieved on: 
Tuesday, June 20, 2023
Workforce, CT scan, Learning, Pediatrics, Education, Educational Strategy for Developing Societies, Neuroimaging, CCTA, Chest pain, Private practice, Neurosurgery, Nuclear medicine, Radiology, Doctor of Philosophy, NASA Outstanding Public Leadership Medal, Practice, RVU, MRI, Magnetic resonance imaging, Patient, Neuroradiology, Reading, MSK, Entrepreneurship, Elective surgery, News, Arnold, Heart, Nursing, Medical imaging, Neuro

CINCINNATI, June 20, 2023 /PRNewswire-PRWeb/ -- Medality, the leading practice development platform for radiologists and imaging organizations, today announced the release of its 2023 Radiology Practice Development Report. This comprehensive report highlights the most critical training gaps and opportunities in radiology and is based on insights from over 2,700 radiologists across 108 countries.

Key Points: 
  • CINCINNATI, June 20, 2023 /PRNewswire-PRWeb/ -- Medality, the leading practice development platform for radiologists and imaging organizations, today announced the release of its 2023 Radiology Practice Development Report .
  • The report reveals that radiologists are reading across an average of 4.7 subspecialty areas in their daily practice, with 40% reporting they read across all radiology subspecialties.
  • The 2023 Radiology Practice Development Report also finds that confidence levels among current readers in each subspecialty varied widely.
  • Highly experienced radiologists are being asked to read in new areas and new technologies that were not part of their training.

Contra Costa Transportation Authority and Beep Partner to Deliver Autonomous Vehicle Projects in California

Retrieved on: 
Friday, April 21, 2023
California Department of Motor Vehicles, Partnership, Travel, California Department, CCTA, City centre, Transport, Beep (smart card), Beep

LAKE NONA, Fla., April 21, 2023 /PRNewswire/ -- Beep Inc., a provider of autonomous shared mobility solutions, today announced a partnership with the Contra Costa Transportation Authority (CCTA). The partnership marks Beep's first West Coast deployment, located at Bishop Ranch in the city of San Ramon, the largest mixed-use business community in Northern California. In 2018, CCTA was the first agency in California to obtain permission by the California Department of Motor Vehicles for a shared autonomous vehicle to travel on public roads in the state.

Key Points: 
  • In 2018, CCTA was the first agency in California to obtain permission by the California Department of Motor Vehicles for a shared autonomous vehicle to travel on public roads in the state.
  • "Having the opportunity to work with a pioneering transportation authority like CCTA is both an honor and a natural partnership," said Beep CEO Joe Moye.
  • This program provides employees, visitors and residents of Bishop Ranch an opportunity to experience autonomous mobility in Beep's autonomous and electric shuttles.
  • Beep and CCTA will partner on delivering autonomous mobility at an additional site early next year.